Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Impact of Alpha Ketoglutarate (AKG), a Geroprotector, in Reducing Morbidity and Improving Patient-Centred Outcomes After Coronary Artery Bypass Grafting Surgery in Resilient and Poorly-Resilient Patients: A Double-Blind Placebo-Controlled Clinical Trial

NCT07031128 is registered in ClinicalTrials.gov with National University Hospital, Singapore as lead sponsor.

NCT NCT07031128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07031128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Impact of Alpha Ketoglutarate (AKG), a Geroprotector, in Reducing Morbidity and Improving Patient-Centred Outcomes After Coronary Artery Bypass Grafting Surgery in Resilient and Poorly-Resilient Patients: A Double-Blind Placebo-Controlled Clinical Trial
Lead sponsor
National University Hospital, Singapore
Phase
Phase 4
Overall status
Recruiting
Start date
June 11, 2024
Completion date
December 31, 2026
Enrollment
250 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cabg